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Abstract
Introduction: The potentially differential roles of both forms of ghrelin in obesity are undefined, and little is known about desacyl ghre-
lin’s (DAG) regulation by meals. We aimed to assess changes in acyl ghrelin (AG) and DAG in response to mixed-meal consumption in 
obese and non-obese subjects.
Material and methods: Venous blood for plasma glucose, AG and DAG assays were collected in both groups after an overnight fast and 
two hours after the consumption of a standard 300 kcal-mixed meal (Nutridrink, Nutricia). 
Results: Mean fasting values of both AG and DAG were significantly lower in the obese individuals. On the other hand, among non-obese 
controls, the mean postprandial DAG levels did not change and AG levels decreased, whereas in obese individuals the mean DAG levels 
after a mixed-meal diminished and AG levels were unchanged.
Conclusions: It is necessary to distinguish between the desacylated and acylated forms of ghrelin, as we have shown differential postpran-
dial AG and DAG responses in obese and non-obese individuals. Whether targeting changed proportions between AG and DAG could be 
a successful strategy in obesity treatment remains a question for future studies. (Endokrynol Pol 2014; 65 (5): 377–381)
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Streszczenie
Wstęp: Niewiele wiadomo jak w otyłości zmienia się wydzielanie obu krążących form greliny — acylowanej (AG) i dezacylowanej (DAG) 
oraz jak posiłek wpływa u otyłych na stężenie DAG. Dlatego autorzy postanowili ocenić zmiany stężeń obu form hormonu przed i po 
posiłku w dwóch grupach: z BMI ≥ 30 i < 30 kg/m2.
Materiał i metody: W obu grupach pobrano krew żylną na czczo i 2 godziny po podaniu standardowego posiłku zawierającego 300 kcal 
(Nutridrink, Nutricia). Oznaczono stężenia obu form greliny.
Wyniki: Stężenia DAG i AG na czczo były niższe w grupie otyłych niż w kontrolnej grupie osób nieotyłych. Po posiłku u osób bez otyłości 
nie zaobserwowano zmian stężenia DAG, a stężenie AG zmalało, podczas gdy u otyłych stężenie DAG uległo istotnemu obniżeniu, a AG 
pozostało bez zmian.
Wnioski: Konieczne jest oznaczanie obu form greliny, gdyż — jak wykazano — zmiany ich stężeń po posiłku mogą być zupełnie odmienne 
u osób otyłych niż w grupie nieotyłych. Odwrócenie zaburzonych proporcji między AG i DAG może okazać się skutecznym sposobem 
leczenia otyłości. (Endokrynol Pol 2014; 65 (5): 377–381)
Słowa kluczowe: grelina dezacylowana; grelina acylowana; otyłość; posiłek
Introduction
Ghrelin, mainly derived from the stomach, is the only 
known orexigenic peptide [1]. It also plays an impor-
tant role in energy metabolism and storage [2]. Plasma 
ghrelin levels fluctuate during the day. They rise before 
meals and fall after ingestion [3]. In normal-weight 
subjects, the postprandial suppression of ghrelin is pro-
portional to the calories consumed [4]. Obese individu-
als have lower fasting ghrelin levels than lean controls 
[5, 6] and it has been demonstrated that they present 
evidently reduced suppression in postprandial ghrelin 
levels [7, 8]. Such dysregulation of ghrelin secretion 
may lead to hyperphagia and reinforce obesity [8, 9].
To date, most studies have assessed total ghrelin 
levels and have not differentiated between AG (acyl-
ghrelin) and DAG (desacyl-ghrelin). As described 
originally by Kojima, the hormone circulates in those 
two forms [1]. Desacylated ghrelin (DAG) was long 
considered to be an inactive degradation product of 
acylated form. The acylation of a peptide is crucial to 
activating GHR1a receptor and exerting many known 
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Blood samples were collected in tubes containing 
EDTA and p-hydroxymercuribenzoic acid to prevent 
the degradation of acyl-ghrelin by protease. They were 
immediately centrifuged at 3,500 x g for 10 min at +4°C 
and kept at –80°C until further analyses were achieved. 
Plasma desacylated and acylated ghrelin levels were 
measured with a commercial enzyme immunoassay 
(Human Acylated Ghrelin EIA Kit, Human Unacylated 
Ghrelin EIA Kit, Biovendor, Czech Republic) in accord-
ance with the supplier’s specifications. DELTA AG was 
then calculated as the difference between fasting and 
2h post mixed-meal AG levels. 
Glucose was measured by the hexokinase method 
(Abbott Laboratories, USA).
In the obese group of patients, fasting additional 
serum samples were collected for total cholesterol, 
high-density lipoprotein cholesterol (HDL-CH), 
low-density lipoprotein cholesterol (LDL-CH), tri-
glycerides (TG), insulin and HbA1c measurements. 
They were analysed on the day of collection. Serum 
lipids concentrations were measured by the oxidase 
method (Abbott Laboratories, USA) and the Friede-
wald formula was used to calculate the LDL-CH 
concentration. Serum insulin levels were determined 
by EIA (Abbott Laboratories, USA). Serum HbA1c 
levels were assessed by Tosoh G8 HPLC Analyser 
(TOSOH, Japan).
Insulin resistance was then estimated using the 
homeostasis model assessment (HOMA-IR), which was 
biological activities of acylated ghrelin (AG) [1]. But 
emerging evidence suggests that the desacylated form 
of the hormone may interact with another unchar-
acterised receptor and induce different physiological 
and metabolic effects independently of AG [10, 11]. 
Moreover, it has been suggested that DAG can either 
antagonise or support the activities of AG [10]. It has 
been reported that DAG has an antagonistic effect on 
AG in relation to appetite stimulation [12]. The poten-
tially differential roles of both forms of ghrelin under 
different pathophysiological conditions such as obesity 
are undefined. 
This study was therefore aimed at comparing fast-
ing and postprandial AG and DAG levels in obese and 
non-obese subjects, using standard mixed macronutri-
ent meals.
Material and methods
The study group consisted of 24 out-clinic patients 
with simple obesity without diabetes mellitus (7 M/17 
F), who were at the beginning of the preparation 
period before bariatric surgery. The control group 
included 13 non-obese healthy volunteers without 
any history of chronic disease, and who were not 
taking any medications (1 M/12 F) Both groups were 
above 18 years old and did not differ with respect to 
age (data presented in Table 1). There were smokers 
in both groups (5/24 among obese and 2/13 among 
controls). The mean BMI in the obese group was 
43.8 kg/m2 (range: 32.5–56.6 kg/m2) and among con-
trols 23.0 kg/m2 (range: 18.1–27.5 kg/m2). Nine persons 
from the obese group were diagnosed with metabolic 
syndrome according to the International Diabetes 
Federation (IDF) criteria. 
The inclusion criteria were BMI > 30 kg/m2 and 
informed consent to the study.
The exclusion criteria were as follows: use of diabetic 
medication, history of cardiovascular incidents, chronic 
liver or renal disease, and pregnancy. The study pro-
tocol was approved by the local university bioethical 
committee. 
After an overnight fast (12 h), waist circumference 
and body weight and body composition with bioim-
pedance analysis (TANITA SC 330) were conducted in 
both groups. The body mass index [BMI: body weight 
(kilograms)/height (metres)2] was then calculated.
Venous blood for plasma glucose, acylated and 
desacylated ghrelin assays were collected in both 
groups after an overnight fast and two hours after the 
consumption of a 300 kcal-mixed meal (mixed-meal 
test, MMT), which consisted of 16% protein, 49% car-
bohydrates and 35% fat (Nutridrink standard 200 ml, 
Nutricia). 
Table I. Characteristics of the studied populations
Tabela I. Charakterystyka badanej populacji
Parameters Obese (n = 24) 
Mean ± SD
Non-obese (n = 13) 
Mean ± SD
Age (years) 35.4 ± 9.1 37.2 ± 9.4
M/F 7/17 1/12 
Smoking 5/24 2/13
BMI [kg/m2] 43.8 ± 6.8a 23.0 ± 3.5
Waist circumference [cm] 129.9 ± 16.1a 76.3 ± 9.3
Fat (%) 46.4 ± 7.6a 27.1 ± 10.1
Fat mass content [kg] 59.9 ± 17.2a 17.9 ± 7.3
Fasting glucose [mg/dL] 89.5 ± 9.2 87.7 ± 7.8
Glucose 2 h MMT [mg/dL] 91.8 ± 18.1b 74.4 ± 6.0
Fasting insulin [µU/mL] 10.7 ± 3.2 –
Insulin 2 h MMT [µU/mL] 23.1 ± 17.4 –
HOMA-IR 2.4 ± 0.9 –
HDL-CH [mg/dL] 44.3 ± 8.8 –
LDL-CH [mg/dL] 124.7 ± 27.9 –
TG [mg/dL] 143.7 ± 50.3 –
ap < 0.00001; bp < 0.001; MMT — mixed-meal test
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calculated in line with the following formula: fasting 
insulin (μU/mL) × fasting glucose (mg/dL)/405 [13]. 
Statistical analysis
The data is expressed as the mean ± SD. The ratio 
of acylated/desacylated ghrelin was calculated for 
fasting and 2h after mixed-meal test values. A Kol-
mogorov-Smirnov test was used to verify whether 
the variable distribution was normal. Differences 
between various parameters of obese and non-obese 
individuals were evaluated by an independent 
Student’s t test and U Mann-Whitney test was used 
when the distribution of the variable was not normal. 
Fasting and postprandial values were compared with 
the use of the paired Student’s t test and Wilcoxon 
signed-range test was used when the distribution 
of the variable was not normal. Spearman’s rank 
correlation coefficient (r) was used to evaluate the 
relationships between the variables. 
Statistical analysis was performed using STATIS-
TICA version 10 (StatSoft, Poland). P values < 0.05 were 
considered as statistically significant.
Results
The general characteristics of both studied populations 
are presented in Table I. Both groups were comparable 
for age, percentage of females and smokers, while BMI, 
fat percentage, fat mass and glucose level 2 h after 
mixed-meal consumption were significantly higher in 
the obese group.
The metabolic and endocrine parameters of the obese 
individuals are included in Table 1. Mean LDL-CH, 
HDL-CH and triglyceride levels amounted to respec-
tively: 124.7 ± 27.9, 44.3 ± 8.8 and 143.7 ± 50.3 mg/dL. 
Fasting and postprandial insulin levels amounted to 
respectively 10.7 ± 3.2 and 23.1 ± 17.4 μU/mL and 
HOMA-IR – 2.40 ± 0.9. 
Average concentrations of AG and DAG before 
and after a meal in the whole group of patients 
(n = 37) did not differ between males and females nor 
between smokers and non-smokers. There were also 
no differences in the average concentrations of the 
above hormones in the subgroups with and without 
metabolic syndrome.
Mean fasting values of both ghrelin forms in the 
obese and non-obese groups are shown in Table II. As 
expected, mean fasting values of both acylated and 
desacylated ghrelin were significantly lower in the 
obese individuals (287 ± 219 vs. 583 ± 369, p = 0.004 
for DAG, and 44 ± 26 vs. 148 ± 56, p < 0.00001 for AG). 
On the other hand, among non-obese controls, the 
mean postprandial DAG levels did not change (583 ± 
369 vs. 532 ± 339; p = 0.64) and AG levels decreased (148 
± 56 vs.122 ± 66; p = 0.01 for AG), whereas in obese 
individuals the mean DAG levels after a mixed-meal 
diminished (287 ± 219 vs. 192 ± 139; p = 0.006) and AG 
levels were unchanged (44 ± 26 vs. 41 ± 23; p = 0.47).
At baseline, the ratio of acylated/desacylated ghrelin 
(AG/DAG) was lower in the obese subjects compared 
to the non-obese ones (22 ± 22 vs. 29 ± 12; p = 0.016). 
However, after a meal, the ratio was similar in both 
groups (obese 33 ± 29 vs. non-obese 30 ± 23; p = 0.95). 
In the whole studied group, we noted a strong nega-
tive correlation between fasting AG levels and waist 
circumference (r = –0.65, p < 0.05), BMI (r = –0.64, 
p < 0.05) and fat mass content (r = –0.58, p < 0.05). 
We found that fasting DAG levels were also nega-
tively correlated with waist circumference, BMI and 
fat mass content, but correlations coefficients (r) were 
lower (respectively –0.55; –0.56 and –0.44; p < 0.05). 
All correlations between both forms of ghrelin and 
other variables in the whole studied group are shown 
in Table III.
Furthermore, we observed a negative correlation 
between DELTA AG (calculated as the differential be-
tween fasting and 2 h post mixed-meal AG levels) and 
HOMA-IR (r = –0.49, p < 0.05) (data presented in Fig. 1). 
Discussion
Since ghrelin was identified in 1999 as the natural 
ligand of growth hormone secretagoque receptor, the 
desacylated form of this peptide has been considered 
to be only an inactive degradation product of acylated 
ghrelin [1]. Therefore many important studies on 
Table II. Fasting and postprandial (2 h MMT) AG and DAG concentrations in obese and non-obese group
Tabela II. Stężenia AG i DAG na czczo i po posiłku (2 h MMT) u otyłych i grupy bez otyłości
Obese (n = 22) Non-obese (n = 12)
Fasting 2 h MMT p Fasting 2 h MMT p
DAG [pg/Ml] 287 ± 219 192 ± 139 0.006 583 ± 369* 532 ± 339* 0.64
AG [pg/mL] 44 ± 26 41 ± 23 0.47 148 ± 56* 122 ± 66* 0.01
AG/DAG 22 ± 22 33 ± 29 0.09 29 ± 12* 30 ± 23 0.95
*p < 0.05 obese vs. non-obese; MMT — mixed-meal test
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ghrelin and energy balance and metabolism have been 
performed with the use of total ghrelin assays measur-
ing total acylated and desacylated ghrelin. McLaughlin 
et al. reported that fasting total ghrelin concentrations 
are higher in insulin-sensitive individuals than in insu-
lin resistant obese subjects [14]. Callahan observed that 
in normal-weight subjects postprandial suppression 
of total ghrelin is proportional to calories consumed 
[4]. The study by le Roux et al. confirmed that total 
ghrelin levels decrease in normal weight individuals 
after mixed meals. However, obese subjects demon-
strated a much reduced total ghrelin postprandial 
suppression [7]. 
It was Broglio et al. who first demonstrated that 
desacylated ghrelin is metabolically active and probably 
counteracts the influence of acylated ghrelin on the hu-
man metabolism. They suggested that DAG should be 
considered as a separate hormone [15]. Soon, Askawa 
et al. reported that DAG has an antagonistic effect on 
ghrelin in relation to appetite stimulation [12]. More 
and more studies suggest that DAG can induce different 
physiological and metabolic effects independently of 
AG [10, 11]. It can also act as an antagonist of acylated 
ghrelin, and therefore probably plays an important role 
in the regulation of food intake and insulin sensitivity. 
Although the inhibition of total ghrelin has been shown 
in the insulin resistance state, specific modulations of 
desacylated and acylated ghrelin remain undefined. 
There are some reports of a differential acute influence 
of AG and DAG on glucose metabolism [16, 17]. It is still 
intriguing as to how the AG/DAG balance could contrib-
ute to the development of obesity. Moreover, changes 
in proportions between AG and DAG induced by meal 
consumption are not fully defined. The mixed-meal test 
(MMT) is an interesting model to examine the changes 
in acylated and desacylated ghrelin profiles. However, 
to the best of our knowledge, no report has assessed the 
changes in plasma AG or DAG levels during a mixed-
meal test in obese and non-obese individuals. 
The present study was therefore designed to as-
sess potential differences in fasting and meal-induced 
levels of both circulating ghrelin forms in obese and 
non-obese individuals. 
We found that mean postprandial DAG levels did 
not change in the control non-obese group, whereas 
AG levels decreased significantly 2 h after a meal. In 
contrast, in obese individuals DAG levels 2 h after a meal 
diminished and AG levels did not change (data present-
ed in Table II). To the best of our knowledge, this is the 
first report assessing DAG changes after a mixed-meal 
in obese individuals compared to non-obese subjects. 
Zwirska et al. studied basal and postprandial plasma 
levels of total and acylated, but not desacylated, ghrelin 
in obese and lean women [18]. They found that acylated 
ghrelin levels dropped significantly after meal ingestion 
and remain decreased 2 h later in lean controls, whereas 
in obese individuals no changes of AG were observed at 
30, 60 and 120 minutes after meal ingestion. The present 
study confirms these observations and previous reports 
that obesity can alter postprandial ghrelin response 
[7, 8]. We also observed that the proportion between 
acylated and desacylated ghrelin are modulated by 
meal consumption in a different manner in obese and 
non-obese individuals. In the fasting state, the ratio of 
acylated/desacylated ghrelin (AG/DAG) was lower in 
obese subjects compared to non-obese ones, but it was 
similar 2 h after the meal. The meal consumption did 
not change the AG/DAG ratio in the non-obese group, 
while AG/DAG tended to be higher after the meal in 
obese individuals, but the p value was not significant 
(p = 0.09). We did not assess the postprandial level of sa-
tiety and we can only speculate that such postprandial 
responses of both ghrelin forms in obese individuals 
may promote hyperphagia. Our results therefore can 
Figure 1. Correlation between DELTA AG (fasting AG — 2 h post 
mixed-meal AG) and HOMA-IR in obese individuals 
Rycina 1. Korelacja między DELTA AG (AG — na czczo 2 godziny 
po posiłku mieszanym AG) i HOMA-IR u osób otyłych
Table III. Correlations between both form of ghrelin and other 
variables in the whole studied group (n = 37)
Tabela III. Korelacje między obiema postaciami greliny 
i innych zmiennych w całej badanej grupie (n = 37)
(n = 37) Fasting AG  
r
Fasting DAG  
r
& waist circumference –0.65* –0.55*
& BMI –0.64* –0.56*
& fat mass –0.58* –0.44*
& fat percentage –0.41* –0.29
& HOMA-IR 0.03 –0.20 
*p < 0.05; R — Spearman’s rank coefficient 
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partially confirm the hypothesis that the dysregulation 
of ghrelin secretion may reinforce obesity [8, 9] and that 
the modulation of altered proportions of both ghrelin 
forms may be a new treatment strategy for obese indi-
viduals. Recently some studies have concentrated on 
the AG/DAG ratio and their impact on the pathogenesis 
of obesity [19–21]. 
St-Pierre et al. evaluated changes of AG and DAG 
during a euglycemic/hyperinsulinemic clamp in obese 
menopausal women. They found a significant reduction 
of AG levels only in an insulin-sensitive subgroup and 
hypothesised that sustained elevation of circulating 
acylated ghrelin levels could contribute to the deteriora-
tion of insulin sensitivity in obese individuals [19]. Our 
study found a significant correlation (r = –0.49, data pre-
sented in Fig. 1) between HOMA-IR and post-meal AG 
changes (DELTA AG). This result is in agreement with 
those of St-Pierre [19] and with the earlier observation 
that postprandial acylated ghrelin levels are correlated 
with insulin sensitivity in obese children suffering from 
Prader-Willi syndrome [22].
Our study also confirmed strong negative correlations 
between fasting AG levels and waist circumference, BMI, 
fat mass amount and percentage (data presented in Table 
III). The relationships between desacylated and acylated 
ghrelin in obesity and insulin resistance state have also 
been studied by Barazzoni et al. [20]. They analysed as-
sociations of both hormone fasting levels with insulin re-
sistance indices (HOMA-IR) in individuals with metabolic 
syndrome. They found that obese patients with metabolic 
syndrome displayed relative AG excess compared to non-
obese metabolic syndrome patients [20]. Obesity then 
could be a state of a relative DAG deficiency, as recently 
proposed by Delhanty et al. [23].
Furthermore, our results underline the importance 
of distinguishing between desacylated and acylated 
forms of ghrelin, as their profile does not have to 
change in the same pattern, especially under different 
pathophysiological conditions such as obesity [22]. We 
have also confirmed the previous authors’ conclusion 
that measuring only the fasting ghrelin concentration is 
unlikely to provide conclusive facts about the physiol-
ogy of ghrelin regulation in humans [19].
The present study’s results are limited by a small 
sample size. Secondly, we assessed ghrelin concentra-
tions only at two time points: fasting and 2 h after a 
meal. However, our results are in agreement with those 
who have studied ghrelin levels at three or more time 
points [18, 19].
Conclusions
Taken together, we have shown differential postpran-
dial acylated and desacylated ghrelin responses in 
obese and non-obese individuals. Whether targeting 
those changed proportions between AG and DAG could 
be a successful strategy in obesity treatment remains 
a question for future studies. 
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